Presentation is loading. Please wait.

Presentation is loading. Please wait.

Clinical Outcomes with β-Blockers for Myocardial Infarction: A Meta-analysis of Randomized Trials  Sripal Bangalore, MD, MHA, Harikrishna Makani, MD,

Published byElena Popovska Modified over 6 years ago

Similar presentations

Presentation on theme: "Clinical Outcomes with β-Blockers for Myocardial Infarction: A Meta-analysis of Randomized Trials  Sripal Bangalore, MD, MHA, Harikrishna Makani, MD,"— Presentation transcript:

1 Clinical Outcomes with β-Blockers for Myocardial Infarction: A Meta-analysis of Randomized Trials 
Sripal Bangalore, MD, MHA, Harikrishna Makani, MD, Martha Radford, MD, Kamia Thakur, MD, Bora Toklu, MD, Stuart D. Katz, MD, James J. DiNicolantonio, PharmD, P.J. Devereaux, MD, PhD, Karen P. Alexander, MD, Jorn Wetterslev, MD, PhD, Franz H. Messerli, MD  The American Journal of Medicine  Volume 127, Issue 10, Pages (October 2014) DOI: /j.amjmed Copyright © 2014 Elsevier Inc. Terms and Conditions

2 Figure 1 Study selection.
The American Journal of Medicine  , DOI: ( /j.amjmed ) Copyright © 2014 Elsevier Inc. Terms and Conditions

3 Figure 2 β-blockers vs controls for the outcome of all-cause mortality in acute myocardial infarction trials. Analysis stratified by reperfusion status. CI = confidence interval; COMMIT = Clopidogrel and Metoprolol in Myocardial Infarction Trial; EMIT = Esmolol Myocardial Ischemia Trial; ICSG = The International Collaborative Study Group; IRR = incident rate ratio; ISIS-1 = First International Study of Infarct Survival Collaborative Group; MEMO = Metoprolol-Morphine Study Group; METOCARD-CNIC = Effect of Metroprolol in Cardioprotection During an Acute Myocardial Infarction trial; MIAMI = Metoprolol in Acute Myocardial Infarction; MILIS = Multicenter Investigation for the Limitation of Infarct Size; RIMA = Rimodellamento Infarcto Miocardico Acuto Study; TIMI = Thrombolysis in Myocardial Infarction; UKCSG = UK Collaborative Study Group. The American Journal of Medicine  , DOI: ( /j.amjmed ) Copyright © 2014 Elsevier Inc. Terms and Conditions

4 Figure 3 β-blockers vs controls for the outcome of myocardial infarction in acute myocardial infarction trials. Analysis stratified by reperfusion status. CI = confidence interval; COMMIT = Clopidogrel and Metoprolol in Myocardial Infarction Trial; EMIT = Esmolol Myocardial Ischemia Trial; ICSG = The International Collaborative Study Group; IRR = incident rate ratio; ISIS-1 = First International Study of Infarct Survival Collaborative Group; MEMO = Metoprolol-Morphine Study Group; METOCARD-CNIC = Effect of Metroprolol in Cardioprotection During an Acute Myocardial Infarction trial; MIAMI = Metoprolol in Acute Myocardial Infarction; MILIS = Multicenter Investigation for the Limitation of Infarct Size; RIMA = Rimodellamento Infarcto Miocardico Acuto Study; TIMI = Thrombolysis in Myocardial Infarction; UKCSG = UK Collaborative Study Group. The American Journal of Medicine  , DOI: ( /j.amjmed ) Copyright © 2014 Elsevier Inc. Terms and Conditions

5 Figure 4 β-blockers vs controls for the outcome of angina pectoris in acute myocardial infarction trials. Analysis stratified by reperfusion status. CI = confidence interval; COMMIT = Clopidogrel and Metoprolol in Myocardial Infarction Trial; EMIT = Esmolol Myocardial Ischemia Trial; ICSG = The International Collaborative Study Group; IRR = incident rate ratio; ISIS-1 = First International Study of Infarct Survival Collaborative Group; MEMO = Metoprolol-Morphine Study Group; METOCARD-CNIC = Effect of Metroprolol in Cardioprotection During an Acute Myocardial Infarction trial; MIAMI = Metoprolol in Acute Myocardial Infarction; MILIS = Multicenter Investigation for the Limitation of Infarct Size; RIMA = Rimodellamento Infarcto Miocardico Acuto Study; TIMI = Thrombolysis in Myocardial Infarction; UKCSG = UK Collaborative Study Group. The American Journal of Medicine  , DOI: ( /j.amjmed ) Copyright © 2014 Elsevier Inc. Terms and Conditions

6 Figure 5 β-blockers vs controls for the outcome of heart failure in acute myocardial infarction trials. Analysis stratified by reperfusion status. CI = confidence interval; COMMIT = Clopidogrel and Metoprolol in Myocardial Infarction Trial; EMIT = Esmolol Myocardial Ischemia Trial; ICSG = The International Collaborative Study Group; IRR = incident rate ratio; ISIS-1 = First International Study of Infarct Survival Collaborative Group; MEMO = Metoprolol-Morphine Study Group; METOCARD-CNIC = Effect of Metroprolol in Cardioprotection During an Acute Myocardial Infarction trial; MIAMI = Metoprolol in Acute Myocardial Infarction; MILIS = Multicenter Investigation for the Limitation of Infarct Size; RIMA = Rimodellamento Infarcto Miocardico Acuto Study; TIMI = Thrombolysis in Myocardial Infarction; UKCSG = UK Collaborative Study Group. The American Journal of Medicine  , DOI: ( /j.amjmed ) Copyright © 2014 Elsevier Inc. Terms and Conditions

7 Figure 6 β-blockers vs controls for the outcome of cardiogenic shock in acute myocardial infarction trials. Analysis stratified by reperfusion status. CI = confidence interval; COMMIT = Clopidogrel and Metoprolol in Myocardial Infarction Trial; EMIT = Esmolol Myocardial Ischemia Trial; ICSG = The International Collaborative Study Group; IRR = incident rate ratio; ISIS-1 = First International Study of Infarct Survival Collaborative Group; MEMO = Metoprolol-Morphine Study Group; METOCARD-CNIC = Effect of Metroprolol in Cardioprotection During an Acute Myocardial Infarction trial; MIAMI = Metoprolol in Acute Myocardial Infarction; MILIS = Multicenter Investigation for the Limitation of Infarct Size; RIMA = Rimodellamento Infarcto Miocardico Acuto Study; TIMI = Thrombolysis in Myocardial Infarction; UKCSG = UK Collaborative Study Group. The American Journal of Medicine  , DOI: ( /j.amjmed ) Copyright © 2014 Elsevier Inc. Terms and Conditions

8 Figure 7 β-blockers vs controls and drug discontinuation in acute myocardial infarction trials. Analysis stratified by reperfusion status. CI = confidence interval; COMMIT = Clopidogrel and Metoprolol in Myocardial Infarction Trial; EMIT = Esmolol Myocardial Ischemia Trial; ICSG = The International Collaborative Study Group; IRR = incident rate ratio; ISIS-1 = First International Study of Infarct Survival Collaborative Group; MEMO = Metoprolol-Morphine Study Group; METOCARD-CNIC = Effect of Metroprolol in Cardioprotection During an Acute Myocardial Infarction trial; MIAMI = Metoprolol in Acute Myocardial Infarction; MILIS = Multicenter Investigation for the Limitation of Infarct Size; RIMA = Rimodellamento Infarcto Miocardico Acuto Study; TIMI = Thrombolysis in Myocardial Infarction; UKCSG = UK Collaborative Study Group. The American Journal of Medicine  , DOI: ( /j.amjmed ) Copyright © 2014 Elsevier Inc. Terms and Conditions

9 Figure 8 β-blockers vs controls for the outcome of all-cause mortality in postmyocardial infarction trials. Analysis stratified by reperfusion status. APSI = Acebutolol et Prévention Secondaire de l'Infarctus; BHAT = Beta-Blocker Heart Attack Trial; CI = confidence interval; CPRG = Coronary Prevention Research Group; EIS = European Infarction Study; IRR = incident rate ratio; JCBMI = The Japanese beta Blockers and Calcium Antagonists Myocardial Infarction; LIT = Lopressor Intervention Trial Research Group. The American Journal of Medicine  , DOI: ( /j.amjmed ) Copyright © 2014 Elsevier Inc. Terms and Conditions

10 Figure 9 β-blockers vs controls for the outcome of myocardial infarction in post myocardial infarction trials. Analysis stratified by reperfusion status. APSI = Acebutolol et Prévention Secondaire de l'Infarctus; BHAT = Beta-Blocker Heart Attack Trial; CI = confidence interval; CPRG = Coronary Prevention Research Group; EIS = European Infarction Study; IRR = incident rate ratio; JCBMI = The Japanese beta Blockers and Calcium Antagonists Myocardial Infarction; LIT = Lopressor Intervention Trial Research Group. The American Journal of Medicine  , DOI: ( /j.amjmed ) Copyright © 2014 Elsevier Inc. Terms and Conditions

11 Figure 10 β-blockers vs controls for the outcome of heart failure in post myocardial infarction trials. Analysis stratified by reperfusion status. APSI = Acebutolol et Prévention Secondaire de l'Infarctus; BHAT = Beta-Blocker Heart Attack Trial; CI = confidence interval; CPRG = Coronary Prevention Research Group; EIS = European Infarction Study; IRR = incident rate ratio; JCBMI = The Japanese beta Blockers and Calcium Antagonists Myocardial Infarction; LIT = Lopressor Intervention Trial Research Group. The American Journal of Medicine  , DOI: ( /j.amjmed ) Copyright © 2014 Elsevier Inc. Terms and Conditions

12 Figure 11 β-blockers vs controls and drug discontinuation in postmyocardial infarction trials. Analysis stratified by reperfusion status. APSI = Acebutolol et Prévention Secondaire de l'Infarctus; BHAT = Beta-Blocker Heart Attack Trial; CI = confidence interval; CPRG = Coronary Prevention Research Group; EIS = European Infarction Study; IRR = incident rate ratio; JCBMI = The Japanese beta Blockers and Calcium Antagonists Myocardial Infarction; LIT = Lopressor Intervention Trial Research Group. The American Journal of Medicine  , DOI: ( /j.amjmed ) Copyright © 2014 Elsevier Inc. Terms and Conditions

13 Figure 12 Trial Sequential Analysis using fixed-effect meta-analysis in the reperfusion era. The required information of 49,990 patients is based on an anticipated intervention effect of 10% relative risk reduction, a control event proportion of 7.36% (estimated from the cumulated comparator event proportion), absence of heterogeneity (diversity = 0%), and α = 0.05 and β = 0.10. The American Journal of Medicine  , DOI: ( /j.amjmed ) Copyright © 2014 Elsevier Inc. Terms and Conditions

14 Figure 13 Meta-regression analysis of the relationship of percentage of patients with reperfusion therapy on the risk ratio of mortality with β-blockers. The American Journal of Medicine  , DOI: ( /j.amjmed ) Copyright © 2014 Elsevier Inc. Terms and Conditions

Download ppt "Clinical Outcomes with β-Blockers for Myocardial Infarction: A Meta-analysis of Randomized Trials  Sripal Bangalore, MD, MHA, Harikrishna Makani, MD,"

Similar presentations

John W. Pickering, PhD, Matthew T. James, MD, PhD, FRCPC, Suetonia C

John W. Pickering, PhD, Matthew T. James, MD, PhD, FRCPC, Suetonia C
Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Patients With Diabetes: A Meta-Analysis  Stavros Stavrakis, MD  The American Journal.

Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Patients With Diabetes: A Meta-Analysis  Stavros Stavrakis, MD  The American Journal.
The Epidemic of the 20th Century: Coronary Heart Disease

The Epidemic of the 20th Century: Coronary Heart Disease
Effect of Renin-Angiotensin System Blockade on Calcium Channel Blocker-Associated Peripheral Edema  Harikrishna Makani, MD, Sripal Bangalore, MD, MHA,

Effect of Renin-Angiotensin System Blockade on Calcium Channel Blocker-Associated Peripheral Edema  Harikrishna Makani, MD, Sripal Bangalore, MD, MHA,
Optimal Systolic Blood Pressure Target After SPRINT: Insights from a Network Meta- Analysis of Randomized Trials  Sripal Bangalore, MD, MHA, Bora Toklu,

Optimal Systolic Blood Pressure Target After SPRINT: Insights from a Network Meta- Analysis of Randomized Trials  Sripal Bangalore, MD, MHA, Bora Toklu,
New-onset Atrial Fibrillation Predicts Heart Failure Progression

New-onset Atrial Fibrillation Predicts Heart Failure Progression
Benefits and risks of using clopidogrel before coronary artery bypass surgery: Systematic review and meta-analysis of randomized trials and observational.

Benefits and risks of using clopidogrel before coronary artery bypass surgery: Systematic review and meta-analysis of randomized trials and observational.
The Evolution of Myocardial Infarction: When the Truths We Hold To Be Self-Evident No Longer Have Evidence  David D. Waters, MD, Sripal Bangalore, MD,

The Evolution of Myocardial Infarction: When the Truths We Hold To Be Self-Evident No Longer Have Evidence  David D. Waters, MD, Sripal Bangalore, MD,
The Effect of Smoking on the Risk of Sciatica: A Meta-analysis

The Effect of Smoking on the Risk of Sciatica: A Meta-analysis
Alfred A. Bartolucci, PhD, Michal Tendera, MD, George Howard, DrPH 

Alfred A. Bartolucci, PhD, Michal Tendera, MD, George Howard, DrPH 
Salt, Tomato Soup, and the Hypocrisy of the American Heart Association

Salt, Tomato Soup, and the Hypocrisy of the American Heart Association
Renato D. Lopes, MD, PhD, Li Li, MS, Christopher B

Renato D. Lopes, MD, PhD, Li Li, MS, Christopher B
Ahmed Abuzaid, MD, Carly Fabrizio, DO, Kevin Felpel, MD, Haitham S

Ahmed Abuzaid, MD, Carly Fabrizio, DO, Kevin Felpel, MD, Haitham S
Duration of Dual Antiplatelet Therapy in Patients with an Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention  Chirag Bavishi, MD, MPH,

Duration of Dual Antiplatelet Therapy in Patients with an Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention  Chirag Bavishi, MD, MPH,
Masaya Koshizaka, MD, PhD, Renato D. Lopes, MD, PhD, MHS, L

Masaya Koshizaka, MD, PhD, Renato D. Lopes, MD, PhD, MHS, L
Impact of More Restrictive Blood Transfusion Strategies on Clinical Outcomes: A Meta- analysis and Systematic Review  Shelley R. Salpeter, MD, Jacob S.

Impact of More Restrictive Blood Transfusion Strategies on Clinical Outcomes: A Meta- analysis and Systematic Review  Shelley R. Salpeter, MD, Jacob S.
Recurrent infarction causes the most deaths following myocardial infarction with left ventricular dysfunction  Stein Ørn, MD, John G.F. Cleland, MD, Matti.

Recurrent infarction causes the most deaths following myocardial infarction with left ventricular dysfunction  Stein Ørn, MD, John G.F. Cleland, MD, Matti.
Prevalence, Predictors, and Outcomes in Treatment-resistant Hypertension in Patients with Coronary Disease  Sripal Bangalore, MD, MHA, Rana Fayyad, PhD,

Prevalence, Predictors, and Outcomes in Treatment-resistant Hypertension in Patients with Coronary Disease  Sripal Bangalore, MD, MHA, Rana Fayyad, PhD,
Early Invasive Versus Initial Conservative Strategies for Women with Non–ST-Elevation Acute Coronary Syndromes: A Nationwide Analysis  Islam Y. Elgendy,

Early Invasive Versus Initial Conservative Strategies for Women with Non–ST-Elevation Acute Coronary Syndromes: A Nationwide Analysis  Islam Y. Elgendy,
Systematic Review and Meta-analysis of Adverse Events of Low-dose Aspirin and Clopidogrel in Randomized Controlled Trials  Kenneth R. McQuaid, MD, Loren.

Systematic Review and Meta-analysis of Adverse Events of Low-dose Aspirin and Clopidogrel in Randomized Controlled Trials  Kenneth R. McQuaid, MD, Loren.

Similar presentations

Ads by Google